Dr. Jacques Turgeon joined Tabula Rasa HealthCare as the Chief Scientific Officer in September, 2015. Prior to joining Tabula Rasa HealthCare, Dr. Turgeon was the Chief Executive Officer of the Centre hospitalier de l’Université de Montréal (CHUM), where we also served as Director of the Centre de Recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) and professor in the Faculty of Pharmacy at the Université de Montréal. From 2005-2007 he was Vice-Rector — Research, Université de Montréal and from 2000-2005, he has served as Dean of the Faculté de pharmacie, Université de Montréal.
Dr. Turgeon received his Bachelor degree in Pharmacy in 1983 from Laval University in Quebec city followed by an M.Sc. degree in pharmacokinetics and a Ph.D. degree in drug metabolism from the same institution in 1985 and 1988, respectively. He completed post-doctoral studies from 1988 to 1990 in the department of Clinical Pharmacology, Vanderbilt University. He joined the Faculty of Pharmacy of Laval University in 1990, and was promoted to the rank of associate professor in 1993 and full professor in 1998. From March 1999 to May 2000, he was Senior Director of the Pharmacokinetics department at Phoenix International Life Sciences.
Research interests of Dr. Turgeon have always been directed towards the study of factors responsible for intersubject variability in drug response. More specifically, he has developed expertise in the role of pharmacogenetics in cardiovascular drug actions. Among his favorite topics were the study of drug-drug interactions leading to pharmacodynamics modulation of antiarrhythmic drug action. Dr. Turgeon has integrated in his research approaches in vitro (patch-clamp technique, in vitro metabolism and molecular biology) models as well as designed and performed studies in healthy volunteers and patients. Dr. Turgeon is recognized internationally for his work on CYP450s and mechanisms of drug-drug interactions. He has published more than 100 referred articles and more than 300 abstracts. Dr. Turgeon has received numerous prizes for his research activities as well as recognition by the students for his teaching skills. He is a member of numerous societies and has been acting on the committees of several granting agencies for several years. He has been the Director of the Quebec Cardiovascular Network of the FRSQ and the Research Director of the Quebec Heart Institute, Laval Hospital.
Dr Turgeon is Professor Emeritus, Université de Montréal; Adjunct professor, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania; Fellow of the Canadian Academy of Sciences and Fellow of the National Academy of Medicine, France.